#United States #Pain Management #Malvern #MAXONA Pharmaceuticals #MAX-001

MAXONA Pharmaceuticals Secures Fifth Patent for MAX-001

Overview of MAX-001

On February 25, 2025, MAXONA Pharmaceuticals proudly announced the issuance of its fifth patent related to MAX-001, the company’s first-to-market product aimed at revolutionizing pain management. This patent, numbered 12,226,421, was granted by the United States Patents and Trademark Office (USPTO) and underscores the company’s commitment to non-opioid solutions in the pharmaceutical landscape.

MAX-001 is formulated as a non-opioid, non-NSAID oral therapy, designed specifically for addressing both acute and chronic pain. With the approval of this patent, MAXONA now possesses a total of five patents concerning the methods of use and composition of nefopam, the active substance in MAX-001.

Corporate Vision and Strategy

Shawn Fatholahi, the President and CEO of MAXONA Pharmaceuticals, highlighted the strategic importance of this intellectual property development. He remarked, _"Our goal has consistently been to strengthen our intellectual property position around MAX-001. The addition of this fifth patent solidifies our commitment to exploring and maximizing the potential of MAX-001 not only for its initial indications but also for future applications. In our pursuit of further development, we will actively seek additional patents for specific use cases and optimal formulations, leveraging our advanced formulation technology and expertise."_

This emphasis on intellectual property signifies the company’s strategic foresight within the competitive pharmaceutical industry, allowing it to navigate both current and future market opportunities effectively.

Research and Development Advancements

MAXONA Pharmaceuticals has made significant strides in the development of MAX-001, bolstered by an experienced management team well-versed in drug development and commercialization. After completing an extensive optimization process, the company successfully executed the Phase 1 clinical program for MAX-001 earlier this year. Looking towards the future, the compound is set to enter Phase 2 clinical trials later in 2025.

Unique Mechanism of Action

MAX-001 is an optimized version of nefopam hydrochloride, characterized as a New Molecular Entity (NME) intended for the treatment of pain in the United States. What sets MAX-001 apart is its ability to provide rapid onset combined with prolonged analgesic effects, primarily achieved through its unique mechanism of action. It acts as a triple neurotransmitter re-uptake inhibitor, exhibiting notably stronger effects on norepinephrine compared to serotonin and dopamine (N > S > D). Upon approval, MAX-001 will stand out as the only triple monoamine re-uptake inhibitor indicated for acute pain treatment in the U.S.

Commitment to Patient-Centric Solutions

Based in Malvern, Pennsylvania, MAXONA Pharmaceuticals is a clinical-stage company focused on delivering innovative therapies that prioritize patient safety and efficacy. The dedicated leadership team possesses extensive knowledge in drug formulation, neuroscience, clinical trial design, and pharmacology, ensuring that the therapies developed are not only effective but also trusted by healthcare providers and patients alike.

The initial focus remains strongly placed on advancing MAX-001, providing a non-opioid therapeutic option designed to tackle the ongoing challenges posed by pain management in clinical settings.

Conclusion

The granting of the fifth patent for MAX-001 marks a pivotal moment for MAXONA Pharmaceuticals as it strives to position itself at the forefront of pain management innovation. With the upcoming Phase 2 trials and a robust plan to enhance its intellectual property portfolio further, MAXONA is well-prepared to contribute significantly to the future of pharmaceutical solutions for pain treatment. As the landscape for non-opioid therapies continues to evolve, MAX-001 may very well set a new standard in the industry.

For more details about MAXONA Pharmaceuticals and their innovative products, visit the official website at www.maxonapharm.com.